Literature DB >> 29763402

Kymriah: A Sign of More Difficult Decisions To Come.

Ed Silverman.   

Abstract

The CAR-T therapy may pass ICER cost-effectiveness muster, but can the health care system afford more drugs like it?

Entities:  

Keywords:  Kymriah; tisagenlecleucel

Mesh：

Substances：

Year:  2018        PMID： 29763402

Source DB:  PubMed          Journal:  Manag Care        ISSN： 1062-3388


  4 in total

Review 1.  Precision medicine in pediatric oncology.

Authors:  Stefan E G Burdach; Mike-Andrew Westhoff; Maximilian Felix Steinhauser; Klaus-Michael Debatin
Journal:  Mol Cell Pediatr       Date:  2018-08-31

2.  The Pathway from Gene Therapy to Genome Editing: A Nightmare or Dream.

Authors:  Mandana Hasanzad; Bagher Larijani
Journal:  Int J Mol Cell Med       Date:  2019-08-25

Review 3.  The concept of justifiable healthcare and how big data can help us to achieve it.

Authors:  Wim van Biesen; Catherine Van Der Straeten; Sigrid Sterckx; Johan Steen; Lisa Diependaele; Johan Decruyenaere
Journal:  BMC Med Inform Decis Mak       Date:  2021-03-06       Impact factor: 2.796

4.  Understanding cell culture dynamics: a tool for defining protocol parameters for improved processes and efficient manufacturing using human embryonic stem cells.

Authors:  J W T Kusena; M Shariatzadeh; R J Thomas; S L Wilson
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.